Shots:

• The approval is based on a (CHS-1420-02) study to evaluate the efficacy, safety & immunogenicity of Yusimry vs Humira in 545 subjects with moderate to severe chronic PsO
• The results showed that Yusimry was equivalent to adalimumab based on the 1EPs, 75% improvement in PASI-75 @12wks. Additionally, the CHS-1420-03 trial assessed the PK bioequivalence of Yusimry vs Humira after SC administration of a single (40mg) dose & demonstrated similarity on all PK endpoints
• Yusimry is Coherus' second FDA-approved product & is expected to launch in the US on July 2023, under the collaboration with AbbVie

Ref: Globe Newswire | Image: Coherus